News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
265,006 Results
Type
Article (13757)
Company Profile (101)
Press Release (251148)
Section
Business (88042)
Career Advice (465)
Deals (15346)
Drug Delivery (67)
Drug Development (36597)
Employer Resources (49)
FDA (6288)
Job Trends (6197)
News (150206)
Policy (14025)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (440)
Adcomms (6)
Allergies (32)
Alliances (23213)
ALS (36)
Alzheimer's disease (384)
Antibody-drug conjugate (ADC) (35)
Approvals (6323)
Artificial intelligence (100)
Autoimmune disease (7)
Automation (3)
Bankruptcy (149)
Best Places to Work (4371)
BIOSECURE Act (9)
Biosimilars (54)
Biotechnology (40)
Bladder cancer (18)
Brain cancer (15)
Breast cancer (74)
Cancer (569)
Cardiovascular disease (67)
Career advice (407)
Career pathing (11)
CAR-T (20)
Cell therapy (81)
Cervical cancer (4)
Clinical research (30842)
Collaboration (319)
Compensation (131)
Complete response letters (16)
COVID-19 (757)
CRISPR (19)
C-suite (112)
Cystic fibrosis (35)
Data (576)
Denatured (15)
Depression (9)
Diabetes (75)
Diagnostics (1315)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (54)
Drug pricing (63)
Drug shortages (12)
Duchenne muscular dystrophy (33)
Earnings (32044)
Editorial (11)
Employer branding (4)
Employer resources (43)
Events (37366)
Executive appointments (346)
FDA (6669)
Featured Employer (20)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (202)
Gene editing (37)
Generative AI (8)
Gene therapy (97)
GLP-1 (336)
Government (1285)
Grass and pollen (2)
Guidances (15)
Healthcare (3564)
Huntington's disease (4)
IgA nephropathy (9)
Immunology and inflammation (33)
Indications (12)
Infectious disease (788)
Inflammatory bowel disease (54)
Inflation Reduction Act (6)
Influenza (12)
Intellectual property (43)
Interviews (59)
IPO (5876)
IRA (29)
Job creations (2050)
Job search strategy (373)
Kidney cancer (6)
Labor market (10)
Layoffs (177)
Leadership (3)
Legal (3429)
Liver cancer (19)
Lung cancer (75)
Lymphoma (50)
Machine learning (1)
Management (16)
Manufacturing (140)
MASH (30)
Medical device (1273)
Medtech (1275)
Mergers & acquisitions (9654)
Metabolic disorders (243)
Multiple sclerosis (17)
NASH (14)
Neurodegenerative disease (21)
Neuropsychiatric disorders (6)
Neuroscience (544)
NextGen: Class of 2025 (1585)
Non-profit (593)
Northern California (663)
Now hiring (7)
Obesity (140)
Opinion (118)
Ovarian cancer (21)
Pain (49)
Pancreatic cancer (13)
Parkinson's disease (41)
Partnered (5)
Patents (102)
Patient recruitment (28)
Peanut (10)
People (28846)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8026)
Phase II (13048)
Phase III (11710)
Pipeline (376)
Podcasts (46)
Policy (58)
Postmarket research (1401)
Preclinical (3206)
Press Release (25)
Prostate cancer (44)
Psychedelics (8)
Radiopharmaceuticals (119)
Rare diseases (156)
Real estate (2633)
Recruiting (17)
Regulatory (10071)
Reports (14)
Research institute (563)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (1)
RSV (6)
Schizophrenia (32)
Series A (35)
Series B (11)
Service/supplier (3)
Sickle cell disease (30)
Southern California (678)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (6)
Startups (1627)
State (2)
Stomach cancer (3)
Supply chain (28)
The Weekly (28)
United States (6724)
Vaccines (149)
Venture capitalists (13)
Webinars (10)
Weight loss (95)
Women's health (8)
Worklife (3)
Date
Today (48)
Last 7 days (186)
Last 30 days (952)
Last 365 days (12067)
2025 (2855)
2024 (12501)
2023 (14246)
2022 (19558)
2021 (20069)
2020 (19036)
2019 (14885)
2018 (11713)
2017 (13889)
2016 (13132)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
Location
Africa (313)
Alabama (13)
Alaska (1)
Arizona (53)
Arkansas (3)
Asia (20082)
Australia (2602)
California (1606)
Canada (862)
China (224)
Colorado (65)
Connecticut (65)
Delaware (51)
Europe (39329)
Florida (298)
Georgia (35)
Idaho (9)
Illinois (179)
India (14)
Indiana (127)
Iowa (1)
Japan (83)
Kansas (55)
Kentucky (12)
Maine (2)
Maryland (245)
Massachusetts (1379)
Michigan (27)
Minnesota (89)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (7)
New Hampshire (6)
New Jersey (699)
New Mexico (7)
New York (466)
North Carolina (374)
North Dakota (2)
Northern California (663)
Ohio (48)
Oklahoma (4)
Oregon (16)
Pennsylvania (405)
Puerto Rico (8)
Rhode Island (7)
South America (501)
South Carolina (2)
Southern California (678)
Tennessee (34)
Texas (215)
Utah (33)
Virginia (69)
Washington D.C. (29)
Washington State (109)
Wisconsin (14)
265,006 Results for "cstone pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
CStone Pharmaceuticals Announces 2024 Annual Results and Recent Business Progress
March 28, 2025
·
13 min read
Press Releases
CStone to Showcase Five Latest Research Achievements at AACR 2025
March 26, 2025
·
7 min read
Press Releases
CStone Partners with SteinCares to Market Sugemalimab in Latin America
January 27, 2025
·
6 min read
Press Releases
CStone Announces Publication of GEMSTONE-303 Study Results for Sugemalimab (Cejemly®) in JAMA
February 25, 2025
·
7 min read
Press Releases
CStone Submits Application to the European Medicines Agency for New Indication of Sugemalimab in Stage III Non-Small Cell Lung Cancer
March 24, 2025
·
5 min read
Press Releases
CStone Announces Inclusion of Cejemly® (sugemalimab) as a First-Line Combination Therapy for NSCLC in ESMO Guideline
February 10, 2025
·
5 min read
Press Releases
CStone Submits Clinical Trial Application in Australia for CS5001 (ROR1 ADC) in Combination with First-Line Standard-of-Care for DLBCL
March 5, 2025
·
5 min read
Press Releases
CStone Announces First Patient Dosed in Global Multicenter Phase I Clinical Trial of CS2009, a PD-1/VEGF/CTLA-4 Trispecific Antibody
March 3, 2025
·
6 min read
Press Releases
CStone Announces Submission of Clinical Trial Application in Australia for CS2009, an Innovative PD-1/VEGF/CTLA-4 Trispecific Antibody
December 23, 2024
·
5 min read
Policy
CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly® (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLC
CStone Pharmaceuticals announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion recommending approval of sugemalimab in combination with chemotherapy as a first-line treatment for metastatic non-small cell lung cancer, which is one of the largest cancer indications and a leading cause of cancer death in the world.
June 1, 2024
·
7 min read
1 of 26,501
Next
